|
1.
|
|
11 p, 396.3 KB |
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma : A subanalysis of OPTIMISMM by clinical characteristics
/
Richardson, Paul G.. (Department of Medical Oncology. Harvard Medical School) ;
Schjesvold, Fredrik (University of Oslo) ;
Weisel, Katja (University Medical Center Hamburg-Eppendorf) ;
Moreau, Philippe (University Hospital Hôtel-Dieu) ;
Anderson, Larry D. (University of Texas Southwestern Medical Center) ;
White, Darrell (Dalhousie University and Queen Elizabeth II Health Sciences Centre) ;
Rodriguez-Otero, Paula (Clínica Universidad de Navarra) ;
Sonneveld, Pieter (Erasmus MC Cancer Institute) ;
Engelhardt, Monika (Universitätsklinikum Freiburg) ;
Jenner, Matthew (University Hospital Southampton NHS Foundation Trust (Regne Unit)) ;
Corso, Alessandro (Hospital of Legnano) ;
Dürig, Jan (University Hospital Essen (Alemanya)) ;
Pavic, Michel (Centre Hospitalier Universitaire De Sherbrooke) ;
Salomo, Morten (Copenhagen University Hospital) ;
Beksac, Meral (Ankara University) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Lindsay, Jindriska (East Kent Hospitals University NHS Foundation Trust) ;
Liberati, Anna Marina (University of Perugia) ;
Galli, Monica (Ospedale Papa Giovanni XXIII. U.O. di Ematologia) ;
Robak, Pawel (Medical University of Lodz) ;
Larocca, Alessandra (A.O.U. Citta della Salute e della Scienza di Torino) ;
Yagci, Munci (Gazi University Medical Faculty) ;
Vural, Filiz (Ege University) ;
Kanate, Abraham (West Virginia University) ;
Jiang, Ruiyun (Bristol Myers Squibb) ;
Grote, Lara (Bristol Myers Squibb) ;
Peluso, Teresa (Celgene International Sàrl. a Bristol-Myers Squibb Company) ;
Dimopoulos, Meletios (National and Kapodistrian University of Athens)
Objective: We evaluated the efficacy and safety of pomalidomide, bortezomib, and dexamethasone (PVd) vs bortezomib and dexamethasone (Vd) by age, renal function, and high-risk cytogenetic abnormalities in lenalidomide-pretreated patients with multiple myeloma at first relapse. [...]
2022 -  10.1111/ejh.13706
European Journal of Haematology, Vol. 108 Núm. 1 (january 2022) , p. 73-83
|
|
|
2.
|
|
16 p, 1.0 MB |
Pomalidomide, Bortezomib, and Dexamethasone in Lenalidomide-Pretreated Multiple Myeloma : A Subanalysis of OPTIMISMM by Frailty and Bortezomib Dose Adjustment
/
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Dimopoulos, Meletios (National and Kapodistrian University) ;
Schjesvold, Fredrik (University of Oslo) ;
Beksac, Meral (Ankara Üniversitesi Tip Fakültes) ;
Facon, Thierry (Hôpital Claude Huriez CHU de Lille) ;
Dhanasiri, Sujith (Celgene International Sàrl. a Bristol-Myers Squibb Company (Suïssa)) ;
Guo, Shien (Evidera) ;
Mu, Yutian (Evidera) ;
Hong, Kevin (Bristol Myers Squibb) ;
Gentili, Christian (Bristol Myers Squibb) ;
Galli, Mónica (ASST Papa Giovanni XXIII) ;
Yagci, Munci (Gazi University) ;
Larocca, Alessandra (University of Torino) ;
Richardson, Paul (Dana-Farber Cancer Institute (Estats Units d'Amèrica)) ;
Weisel, Katja (University Medical Center Hamburg-Eppendorf (Alemanya))
Introduction: A proportion of patients with multiple myeloma (MM) are older and/or have comorbidities, requiring dose adjustments. Data from OPTIMISMM (NCT01734928) supported the use of pomalidomide, bortezomib, and dexamethasone (PVd) for treating relapsed/refractory MM. [...]
2023 - 10.1016/j.clml.2023.10.009
Clinical Lymphoma, Myeloma & Leukemia, 2023
|
|
|
3.
|
|
10 p, 306.4 KB |
Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone : analyses from the Phase II HORIZON study
/
Larocca, Alessandra (Azienda Ospedaliero - Universitaria Città della Salute e della Scienza) ;
Leleu, Xavier (CHU de Poitiers) ;
Touzeau, Cyrille (Université d'Angers) ;
Bladé Creixenti, Juan (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Paner, Agne (Rush University Medical Center) ;
Mateos, M. V (Instituto de Investigación Biomédica de Salamanca) ;
Cavo, Michele (Bologna University School of Medicine) ;
Maisel, Christopher (Baylor Scott & White Charles A) ;
Alegre, Adrian (Hospital Universitario de la Princesa (Madrid)) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Raptis, Anastasios (niversity of Pittsburgh School of Medicine) ;
Rodriguez-Otero, Paula (Clínica Universidad de Navarra) ;
Mazumder, Amitabha (The Oncology Institute of Hope and Innovation) ;
Laubach, Jacob (Harvard Medical School) ;
Nadeem, Omar (Harvard Medical School) ;
Sandberg, Anna (Oncopeptides AB (Suècia)) ;
Orre, Marie (Oncopeptides AB (Suècia)) ;
Torrång, Anna (SDS Life Science (Suècia)) ;
Bakker, Nicolaas A (Oncopeptides AB) ;
Richardson, Paul G.. (Harvard Medical School) ;
Universitat Autònoma de Barcelona
Relapsed/refractory multiple myeloma (RRMM) is known to have a high burden of disease and complications associated with refractoriness to prior lines of therapy. Severe pain and fatigue symptoms and impairments in physical and emotional functioning have been strongly linked to reduced health-related quality of life (HRQoL) in patients with RRMM. [...]
2022 - 10.1111/bjh.17887
British Journal of Haematology, Vol. 196 Núm. 3 (february 2022) , p. 639-648
|
|
|
4.
|
|
13 p, 449.0 KB |
Melflufen and dexamethasone in heavily pretreated relapsed and refractory multiple myeloma
/
Richardson, Paul G.. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica). Harvard Medical School) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Larocca, Alessandra (Università di Torino. Azienda Ospedaliero-Universitaria Città della Salute e della Scienza) ;
Bladé Creixenti, Juan (Hospital Clínic i Provincial de Barcelona) ;
Cavo, Michele (Seràgnoli Institute of Hematology. Bologna University School of Medicine) ;
Rodriguez-Otero, Paula (Clínica Universidad de Navarra) ;
Leleu, Xavier (CHU de Poitiers) ;
Nadeem, Omar (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica). Harvard Medical School) ;
Hiemenz, John W. (Division of Hematology-Oncology. Department of Medicine. University of Florida) ;
Hassoun, Hani (Memorial Sloan Kettering Cancer Center) ;
Touzeau, Cyrille (Université de Nantes) ;
Alegre, Adrian (Hospital Universitario de la Princesa (Madrid)) ;
Paner, Agne (Rush University Medical Center) ;
Maisel, Christopher (Baylor Scott & White Charles A. Sammons Cancer Center) ;
Mazumder, Amitabha (Oncology Institute of Hope and Innovation) ;
Raptis, Anastasios (Universityof Pittsburgh School of Medicine) ;
Moreb, Jan S. (Novant Health Hematology. Novant Health Forsyth Medical Center) ;
Anderson, Kenneth C. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica). Harvard Medical School) ;
Laubach, Jacob P. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica). Harvard Medical School) ;
Thuresson, Sara (Oncopeptides AB) ;
Thuresson, Marcus (Oncopeptides AB) ;
Byrne, Catriona (Oncopeptides AB) ;
Harmenberg, Johan (Oncopeptides AB) ;
Bakker, Nicolaas A. (Oncopeptides AB) ;
Mateos, M. V (Hospital Clínico Universitario (Salamanca))
PURPOSE Melphalan flufenamide (melflufen) is a first-in-class peptide-drug conjugate that targets aminopeptidases and rapidly and selectively releases alkylating agents into tumor cells. The phase II HORIZON trial evaluated the efficacy of melflufen plus dexamethasone in relapsed and refractory multiple myeloma (RRMM), a population with an important unmet medical need. [...]
2021 - 10.1200/JCO.20.02259
Journal of Clinical Oncology, Vol. 39 Núm. 7 (january 2021) , p. 757-767
|
|
|
5.
|
|
11 p, 1.3 MB |
Melflufen for relapsed and refractory multiple myeloma
/
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Larocca, Alessandra (Azienda Ospedaliero-Universitaria Città Della Salute E Della Scienza Di Torino. University of Torino) ;
Leleu, Xavier (Department of Hematology. CHU De Poitiers) ;
Hájek, R (Department of Hemato-Oncology. University of Ostrava and Faculty of Medicine. University of Ostrava) ;
Hassoun, Hani (Memorial Sloan Kettering Cancer Center) ;
Rodríguez-Otero, P. (Clínica Universidad de Navarra) ;
Paner, A. (Division of Hematology. Oncology and Stem Cell Transplant. Rush University Medical Center) ;
Schjesvold, F. H. (Oslo Myeloma Center. Oslo University Hospital and K.G. Jebsen Centre for B-Cell Malignancies. University of Oslo) ;
Gullbo, J. (Department of Medical Sciences. Division of Clinical Pharmacology. Uppsala University) ;
Richardson, Paul G.. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica). Jerome Lipper Multiple Myeloma Center) ;
Universitat Autònoma de Barcelona
Introduction: The overall survival of patients with multiple myeloma has improved with the advent of novel agents; however, multiple myeloma remains incurable. Combinations of standard-of-care agents such as immunomodulators, proteasome inhibitors, and anti-CD38 monoclonal antibodies are increasingly used in earlier lines of therapy. [...]
2020 - 10.1080/13543784.2020.1808884
Expert Opinion on Investigational Drugs, Vol. 29 Núm. 10 (february 2020) , p. 1069-1078
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
